JPMorgan upgraded Novartis (NVS) to Overweight from Neutral with a price target of CHF 125, up from CHF 95. The firm adjusted ratings in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports
- Novartis price target raised to $143 from $136 at Morgan Stanley